Biomednewsbreaks - Annovis Bio Inc. (NYSE: ANVS) Enrolls First Patients In Phase 3 Alzheimer's Trial
(MENAFN- Investor Brand Network) Annovis Bio (NYSE: ANVS) announced that the first two patients have been enrolled in its pivotal Phase 3 trial evaluating buntanetap for early Alzheimer's disease. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback